home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

217.99 -16.65 (-7.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

25 26 Next >

The Top Healthcare Stocks to Buy With $100 ↗

June 09, 2023

You don't need a fortune to start investing.

Via The Motley Fool

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

June 01, 2023

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 30, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics's Return On Capital Employed Overview ↗

May 22, 2023

Via Benzinga

3 Growth Stocks to Buy and Hold ↗

May 13, 2023

These three stocks defied the bear market last year.

Via The Motley Fool

Expert Ratings for Axsome Therapeutics ↗

May 09, 2023

Via Benzinga

Earnings Outlook For Axsome Therapeutics ↗

May 05, 2023

Via Benzinga

Prediction: These 2 Stocks Could Double In the Next Year ↗

May 28, 2023

It would be a continuation of solid recent performances.

Via The Motley Fool

2 Biotech Stocks That Could Help Set You Up for Life ↗

May 26, 2023

These two promising companies have the potential to beat the market over time.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 22, 2023

Via Benzinga

2 Bear Market Defying Stocks to Buy in May ↗

May 22, 2023

These stocks still have plenty of market-beating years ahead.

Via The Motley Fool

2 Unstoppable Growth Stocks to Buy in 2023 and Beyond ↗

May 20, 2023

Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines.

Via The Motley Fool

Is a Victory for Its Rivals Bad News for Axsome Therapeutics? ↗

May 17, 2023

The biopharmaceutical company's shares have soared during the past year.

Via The Motley Fool

Axsome Therapeutics Stock: Bear vs. Bull ↗

April 23, 2023

Axsome shares beat the bear market last year.

Via The Motley Fool

Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review ↗

May 12, 2023

The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.

Via Investor's Business Daily

This Analyst Creates Bullish Pitch For Axsome Therapeutics On Increased Outlook For Its Depression Drug ↗

May 11, 2023

Mizuho increased the price target on Axsome Therapeutics Inc (NASDAQ: AXSM) from $84 to $95 with a Buy rating

Via Benzinga

2 Magnificent Growth Stocks You Can Buy With $150 Right Now ↗

May 10, 2023

You don't have to wait until you're rich to start getting your money to work for you.

Via The Motley Fool

Axsome's New Drug Is Scoring a Win. Is the Stock a Buy? ↗

May 09, 2023

The biotech's share price more than doubled during last year's bear market.

Via The Motley Fool

Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage ↗

May 08, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and

Via Benzinga

Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript ↗

May 08, 2023

AXSM earnings call for the period ending March 31, 2023.

Via The Motley Fool

Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite. ↗

May 08, 2023

Axsome shares are nearing a breakout point. But BioXcel crumbled on its report.

Via Investor's Business Daily

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

May 08, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

May 03, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

May 01, 2023

One World Trade Center to be lit up in green in observance of Mental Health Month

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy ↗

April 28, 2023

Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023

Via InvestorPlace

NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc. ↗

April 27, 2023

San Diego, CA -- (SBWIRE) -- 04/27/2023 -- Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat ↗

April 25, 2023

Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat.

Via InvestorPlace

If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now ↗

April 25, 2023

Axsome's new products have blockbuster potential.

Via The Motley Fool

3 Stocks With Huge Catalysts on the Way ↗

April 22, 2023

Big news could mean big boosts for these stocks.

Via The Motley Fool

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of

April 21, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com